Gilead's cell therapy head Christi Shaw leaving next month
2023年2月17日 · When Christi Shaw joined Gilead Sciences's CAR-T outfit Kite Pharma back in 2019, the company had one approved cell therapy chipping in modestly toward overall growth. Now, after more than...
Christi Shaw - Family Reach - LinkedIn
Christi Shaw has built a highly coordinated, patient-focused team at Kite united around the mission to cure cancer, which has led to a period of explosive growth for the company.
- 500+ 连接数
- 位置: Family Reach
The Remarkable Story of Pharma CEO Christi Shaw Who Took a ...
2022年4月8日 · Kite Pharma and Christi Shaw, the company's CEO, are pushing innovative cancer treatments forward as leaders in the field. And this time, adult patients with acute lymphoblastic leukemia are the ones who will benefit.
Christi Shaw to Depart Gilead and Kite Leadership End of Q1
2023年2月17日 · Foster City and Santa Monica, Calif. – February 17, 2023 – Christi Shaw has decided to leave Kite, a Gilead Company, effective end of March.
Gilead’s Shaw to step down from role running cell therapy unit
2023年2月17日 · Top Gilead Sciences executive Christi Shaw will leave the company at the end of March after more than three years running the drugmaker’s Kite cell therapy division, Gilead annnounced Friday.
Kite Pharma’s Christi Shaw on the story behind her drive
Christi Shaw, former CEO, Kite, a Gilead Company, talks to Isabel O’Brien about her why she joined the pharmaceutical industry, what drives her passion for developing CAR T-cell therapy and her professional and personal goals for the future
Christi Shaw, Former CEO of Kite, a Gilead Company ... - Cellares
2024年3月26日 · Shaw’s strategic leadership at Kite Pharma resulted in achieving regulatory approval and subsequent commercialization of both Yescarta and Tecartus. Her expertise will be pivotal in accelerating the adoption of Cellares’ IDMO Smart Factories, which are capable of producing 10 times as many cell therapies as conventional CDMO facilities with ...
Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed ...
2024年3月26日 · Shaw’s strategic leadership at Kite Pharma resulted in achieving regulatory approval and subsequent commercialization of both Yescarta and Tecartus.
Christi Shaw, CEO of Gilead's Kite Pharmaceuticals, to depart
2023年2月17日 · C hristi Shaw, the CEO of Gilead’s Kite Pharmaceuticals cell therapy unit, is leaving the company, Gilead said Friday in a statement. Shaw, who took the Kite role in July 2019, had...
BRIEF—Christi Shaw to quit as CEO of Kite | The Pharmaletter
2023年2月20日 · Christi Shaw has decided to leave her post as head of Gilead Sciences’ Kite cell therapy unit, effective end of March. Daniel O'Day, chairman and chief executive of Gilead, will work closely with Ms Shaw and the Kite leadership team over the next few weeks to ensure a smooth transition while a search is conducted for a new leader for Kite.
- 某些结果已被删除